You can read the IBTA e-News August 2018 edition in full online here.
Some of the highlights from this month's round-up:
- The 2017 National Cancer Patient Experience Survey has been published in the UK, offering a snapshot of cancer patients’ experiences of their care in England. Brain and CNS tumour patients reported improvements since the previous year but continued to have among the lowest patient experience scores of all cancer types.
- Results of the TAVAREC randomised controlled phase 2 trial of bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma (without 1p/19q co-deletion) have shown “no evidence of improved survival”, according to findings published in The Lancet Oncology.
- Results from a phase 2 clinical trial of the checkpoint inhibitors ipilimumab and nivolumab in patients with melanoma skin cancer that had spread to the brain found that the therapy had “clinically meaningful” effects: 26 percent had a complete response, 30 percent had a partial response and 2 percent had stable disease.
- A large multinational study has found no association between occupational electromagnetic field (EMF) exposure and glioma or meningioma diagnosis, according to an article published in the journal Environment International.
- A new symptoms diary has been published by HeadSmart, a UK-based awareness campaign which aims to reduce brain tumour diagnosis times in children and teenagers by helping parents and healthcare professionals better recognise the signs and symptoms.
- A paper published in Nature Medicine has offered an explanation for the apparent lack of the T-cell class of immune cells in the bloodstream of glioblastoma brain tumour patients. The researchers found that the “missing” T-cells appear in large numbers within the bone marrow and suggest future research into agents that can free these trapped cells, potentially improving the effectiveness of existing and new immunotherapies.
- We are delighted to announce that IBTA Co-Director Kathy Oliver will be speaking about the All.Can patient survey at a ‘New Horizon’ session at the European Cancer Summit (ECCO 2018) “From Science to Real-Life Oncology”, which takes place from 7 - 9 September, in Vienna, Austria.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.